Ignite Creation Date:
2024-05-05 @ 4:51 PM
Last Modification Date:
2024-10-26 @ 9:25 AM
Study NCT ID:
NCT00329264
Status:
COMPLETED
Last Update Posted:
2009-03-25
First Post:
2006-05-22
Brief Title:
Safety Efficacy Study of Quetiapine Fumarate SEROQUEL vs Placebo in Generalized Anxiety Disorder
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
A Multicenter Randomized Double-Blind Parallel-Group Placebo-Controlled Study of the Efficacy and Safety of Sustained-Release Quetiapine Fumarate SEROQUEL Compared With Placebo in the Treatment of Generalized Anxiety Disorder
Status:
COMPLETED
Status Verified Date:
2009-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
TITANIUM
Brief Summary:
The purpose of this study is to demonstrate that quetiapine SR SEROQUEL is efficacious and safe in the acute treatment of patients with Generalized Anxiety Disorder
PLEASE NOTE Seroquel SR and Seroquel XR refer to the same formulation The SR designation was changed to XR after consultation with FDA
PLEASE NOTE Seroquel SR and Seroquel XR refer to the same formulation The SR designation was changed to XR after consultation with FDA
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| Titanium | None | None | None |